These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38670407)

  • 1. Determination of arbutin in vitro and in vivo by LC-MS/MS: Pre-clinical evaluation of natural product arbutin for its early medicinal properties.
    Wang QL; Zhang PX; Shen R; Xu M; Han L; Shi X; Zhou ZR; Yang JY; Liu JQ
    J Ethnopharmacol; 2024 Aug; 330():118232. PubMed ID: 38670407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Avitinib on CYP450 Enzyme Activity in vitro and in vivo in Rats.
    Shi Y; Meng D; Wang S; Geng P; Xu T; Zhou Q; Zhou Y; Li W; Chen X
    Drug Des Devel Ther; 2021; 15():3661-3673. PubMed ID: 34456561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Caffeic Acid and Quercetin on In Vitro Permeability, Metabolism and In Vivo Pharmacokinetics of Melatonin in Rats: Potential for Herb-Drug Interaction.
    Jana S; Rastogi H
    Eur J Drug Metab Pharmacokinet; 2017 Oct; 42(5):781-791. PubMed ID: 28070878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, plasma protein binding, and metabolism of a potential natural chemosensitizer from Marsdenia tenacissima in rats.
    Xie B; Jiang SQ; Shen XL; Wu HQ; Hu YJ
    J Ethnopharmacol; 2021 Dec; 281():114544. PubMed ID: 34419608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the in vitro metabolism of psoralidin among different species and characterization of its inhibitory effect against UDP- glucuronosyltransferase (UGT) or cytochrome p450 (CYP450) enzymes.
    Shi X; Zhang G; Mackie B; Yang S; Wang J; Shan L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Sep; 1029-1030():145-156. PubMed ID: 27428458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo and in vitro metabolism and pharmacokinetics of cholinesterase inhibitor deoxyvasicine from aerial parts of Peganum harmala Linn in rats via UPLC-ESI-QTOF-MS and UPLC-ESI-MS/MS.
    Deng G; Liu W; Ma C; Rong X; Zhang Y; Wang Y; Wu C; Cao N; Ding W; Guan H; Cheng X; Wang C
    J Ethnopharmacol; 2019 May; 236():288-301. PubMed ID: 30872168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.
    Venkatesh PR; Goh E; Zeng P; New LS; Xin L; Pasha MK; Sangthongpitag K; Yeo P; Kantharaj E
    Biol Pharm Bull; 2007 May; 30(5):1021-4. PubMed ID: 17473456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies of pharmacokinetics in beagle dogs and drug-drug interaction potential of a novel selective ZAK inhibitor 3h for hypertrophic cardiomyopathy treatment.
    Jiang W; Ding L; Dai T; Guo J; Dai R; Chang Y
    J Pharm Biomed Anal; 2019 Aug; 172():206-213. PubMed ID: 31060033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical comprehensive physicochemical and pharmacokinetic profiling of novel nitroimidazole derivative IIIM-019 - A potential oral treatment for tuberculosis.
    Kour G; Kumar A; Singh PP; Sharma S; Bhagat A; Vishwakarma RA; Ahmed Z
    Pulm Pharmacol Ther; 2016 Oct; 40():44-51. PubMed ID: 27457685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism and pharmacokinetics characterization of metarrestin in multiple species.
    Padilha EC; Shah P; Wang AQ; Singleton MD; Hughes EA; Li D; Rice KA; Konrath KM; Patnaik S; Marugan J; Rudloff U; Xu X
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):805-816. PubMed ID: 32185484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma protein binding, pharmacokinetics, tissue distribution and CYP450 biotransformation studies of fidarestat by ultra high performance liquid chromatography-high resolution mass spectrometry.
    Borkar RM; Bhandi MM; Dubey AP; Nandekar PP; Sangamwar AT; Banerjee SK; Srinivas R
    J Pharm Biomed Anal; 2015 Jan; 102():386-99. PubMed ID: 25459938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic profiling of lumateperone in vitro and in vivo by UPLC-Q Exactive Orbitrap HRMS, and its pharmacokinetic study in rat plasma by LC-MS/MS.
    Qiu Y; Guo J; Chen J; Zhang W; Wang W
    J Pharm Biomed Anal; 2024 Aug; 246():116221. PubMed ID: 38759324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herb-drug interaction between Styrax and warfarin: Molecular basis and mechanism.
    Zhang F; Huang J; He RJ; Wang L; Huo PC; Guan XQ; Fang SQ; Xiang YW; Jia SN; Ge GB
    Phytomedicine; 2020 Oct; 77():153287. PubMed ID: 32739573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.
    Kumar V; Schuck EL; Pelletier RD; Farah N; Condon KB; Ye M; Rowbottom C; King BM; Zhang ZY; Saxton PL; Wong YN
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):229-37. PubMed ID: 21698359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elucidation of plasma protein binding, blood partitioning, permeability, CYP phenotyping and CYP inhibition studies of Withanone using validated UPLC method: An active constituent of neuroprotective herb Ashwagandha.
    Singh SK; Valicherla GR; Bikkasani AK; Cheruvu SH; Hossain Z; Taneja I; Ahmad H; Raju KSR; Sangwan NS; Singh SK; Dwivedi AK; Wahajuddin M; Gayen JR
    J Ethnopharmacol; 2021 Apr; 270():113819. PubMed ID: 33460762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of LC-MS/MS method for quantification of novel PP2A - β-catenin signalling inhibitor, S011-2111 in mice plasma: Application to its preclinical pharmacokinetic studies.
    Riyazuddin M; Husain A; Valicherla GR; Verma S; Gupta AP; Praveena KS; Singh A; Avula SR; Sashidhara KV; Datta D; Gayen JR
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Nov; 1130-1131():121829. PubMed ID: 31670104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flavokawain A inhibits Cytochrome P450 in in vitro metabolic and inhibitory investigations.
    Niu L; Ding L; Lu C; Zuo F; Yao K; Xu S; Li W; Yang D; Xu X
    J Ethnopharmacol; 2016 Sep; 191():350-359. PubMed ID: 27318274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of in vitro metabolic stability, plasma protein binding, and pharmacokinetics of E- and Z-guggulsterone in rat.
    Chhonker YS; Chandasana H; Mukkavilli R; Prasad YD; Laxman TS; Vangala S; Bhatta RS
    Drug Test Anal; 2016 Sep; 8(9):966-75. PubMed ID: 26608935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS.
    Di L; Kerns EH; Li SQ; Carter GT
    Int J Pharm; 2007 Apr; 335(1-2):1-11. PubMed ID: 17137735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.